Core Viewpoint - European stocks rose as better-than-expected U.S. personal consumption expenditure data boosted investor sentiment, overshadowing President Trump's proposed tariffs on patented drugs [1] Group 1: Market Performance - The Stoxx Europe 600 index closed up 0.8% [1] - The healthcare sector erased earlier losses, closing up 0.1% despite Trump's announcement of a 100% tariff on patented drugs starting October 1, unless manufacturers establish production in the U.S. [1] Group 2: Company Reactions - Novo Nordisk's stock fell by 3.5%, and Zealand Pharma's stock dropped by 2.4% following the tariff announcement [1] - Bank J. Safra Sarasin's equity strategist, Wolf von Rotberg, indicated that the lack of policy details and the limited number of affected drugs would not lead to a reduction in pharmaceutical sector holdings [1] Group 3: Investment Strategy - Sophie Huynh, a portfolio manager and strategist at Société Générale, suggested that the current situation might be a good time to increase holdings in European stocks rather than shorting them [1] - The pharmaceutical sector's performance is highly dependent on specific countries, and while the current situation may create market tension, investors should maintain a broader perspective [1]

Group 1 - European stock markets opened higher, with the Stoxx 600 index rising by 0.3%, indicating a lack of excessive reaction from investors to President Trump's threat of imposing tariffs on patented drugs [1] - The healthcare sector experienced a slight decline of 0.2%, with notable drops in companies such as Novo Nordisk, which fell by 1.7%, and Zealand Pharma, which decreased by 2.2% [1] - Sophie Huet, a portfolio manager and strategist at BNP Paribas Asset Management, suggested that this situation could present a buying opportunity rather than a reason to short European stocks, emphasizing the importance of considering the broader context despite the sector's national characteristics [1] Group 2 - European stock markets have been fluctuating within a narrow range as investors assess the prospects of interest rate cuts in the U.S. [3] - Market attention is shifting towards the U.S. Federal Reserve's preferred inflation indicator, the Personal Consumption Expenditures Price Index, for insights into the economic situation [3] - STMicroelectronics saw a decline of 1.6% following reports that the Trump administration is considering plans to reduce U.S. dependence on foreign chips [3]

By Gregor Stuart Hunter and Andrew Silver SINGAPORE/SHANGHAI (Reuters) -Shares of U.S. and European pharmaceutical firms were little changed on Friday, while Asian drugmakers declined, after President Donald Trump announced 100% tariffs on branded drugs imported by firms that are not building plants in the U.S. Analysts said the move was widely expected and unlikely to materially hit the industry, given that most drugmakers have pledged billions of dollars in U.S. manufacturing investments. The condit ...

Summary of Zealand Pharma Conference Call Company Overview - **Company**: Zealand Pharma (OTCPK:ZLDP.Y) - **Date**: September 25, 2025 - **Key Speaker**: David M. Kendall, Chief Medical Officer Core Industry Insights Partnership and Product Development - Zealand Pharma has established a partnership with Roche, focusing on the petrelintide asset, which is progressing towards phase 3 trials [3][5] - Ongoing phase 2 studies are expected to yield results in the first half of next year [3] - The company aims to position itself as a key player in the obesity and metabolism space, beyond its existing Zegalogue franchise [4] Market Dynamics - The obesity market is evolving rapidly, with projections indicating that 40% to 50% of the global population will be overweight or obese in the coming decade [8] - There is a shift towards patient-driven demand for weight management therapies, contrasting with traditional provider-driven approaches [9][10] - Zealand Pharma believes that amylin-based therapies, particularly petrelintide, could become foundational in managing obesity [4][5] Product-Specific Insights Petrelintide Development - Petrelintide is expected to achieve weight loss comparable to GLP-1 therapies, with estimates of mid-teens to 20% weight loss [12][13] - The phase 2b trial aims to leverage tolerability and lower starting doses with monthly dose escalations [19] - The trial design will focus on a representative population, including a balanced gender ratio and higher BMI [20] Competitive Landscape - Petrelintide is positioned as a better-in-class option compared to other amylin agonists, with a 100% response rate in early studies [26] - The adverse event profile of petrelintide is expected to be favorable compared to competitors like kagrelintide and LRL-NTIDE [28][30] - Zealand Pharma is confident in the safety and efficacy of petrelintide, with no significant neuropsychiatric side effects reported [36][37] Regulatory and Market Considerations - The regulatory landscape is evolving, with expectations for higher efficacy and tolerability standards for new therapies [44][45] - Zealand Pharma is monitoring the potential for oral formulations but believes that injectables will remain the dominant delivery method in the obesity market [48][50] Future Outlook - Zealand Pharma is optimistic about the potential of petrelintide and its partnership with Roche to capture a significant share of the obesity market [11][35] - The company is preparing for phase 3 trials and is focused on optimizing trial designs to meet regulatory requirements and market needs [12][14] Conclusion - Zealand Pharma is strategically positioned in the growing obesity market with innovative therapies like petrelintide, backed by a strong partnership with Roche and a focus on patient-driven demand for weight management solutions [5][11]

Group 1 - Roche aims to become a top three player in the global obesity market, competing with Novo Nordisk and Eli Lilly as it advances its experimental weight-loss drug to late-stage trials [1][2] - The company announced that its CT-388 weight loss injection is entering phase III trials, which is the final stage before seeking regulatory approval, indicating progress in Roche's obesity treatment pipeline [2] - Roche plans to launch its suite of obesity treatments by 2030, despite currently having no approved obesity drugs on the market [2] Group 2 - Roche is co-developing the Petrelintide drug candidate in a $5.3 billion partnership with Zealand Pharma, which is a significant step in its obesity treatment strategy [3] - Petrelintide is an amylin analog that complements Roche's existing GLP-1 offerings, including CT-388 and CT-996, acquired through the purchase of Carmot Therapeutics in late 2023 [4] - The company is committed to accelerating the timeline for Petrelintide's development [3]

Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Rachel James-Owens as Vice President, Corporate Communications & Media Relations. Rachel brings over 20 years of global pharmaceutical experie ...

Core Insights - Zealand Pharma has appointed Rachel James-Owens as Vice President of Corporate Communications & Media Relations, bringing over 20 years of experience in the pharmaceutical industry [1][2]. Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines, with more than 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [4]. - The company was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. [5]. Leadership Commentary - Adam Steensberg, CEO of Zealand Pharma, expressed enthusiasm about Rachel's appointment during a pivotal growth phase for the company, highlighting her extensive communications leadership experience as invaluable [3]. - Rachel James-Owens emphasized the exciting pipeline and growth strategy of Zealand Pharma, noting the company's collaborative culture and her eagerness to contribute to its long-term impact [3].

Core Insights - Zealand Pharma is exploring a direct-to-patient sales model for its experimental weight-loss drug, in addition to traditional sales through insurers [1] - The CEO highlighted a shift in the market dynamics that may support this new sales approach [1] Company Strategy - The company is considering a dual-channel strategy that includes both direct-to-patient sales and traditional insurer channels [1] - This strategy aims to enhance accessibility and potentially increase the market reach of the weight-loss drug [1] Market Dynamics - The CEO's comments reflect a broader trend in the pharmaceutical industry towards more direct engagement with patients [1] - The shift in market dynamics may be influenced by changing consumer preferences and the increasing importance of patient-centric models [1]

Core Viewpoint - Roche plans to advance its experimental weight loss drug CT-388 to late-stage trials next year, aiming to compete with leading companies like Eli Lilly and Novo Nordisk in the weight loss market [1] Company Summary - Roche's CT-388 faced a significant stock price drop last year due to early research revealing side effects such as nausea and vomiting, but the company emphasized that the incidence of these side effects is comparable to competitors [1] - Roche has entered a $5.3 billion collaboration with a New Zealand pharmaceutical company to co-develop Zealand's weight loss drug, while also having another weight loss drug in its own pipeline [1] - CT-388 has a similar mechanism of action to Eli Lilly's flagship product Zepbound, promoting satiety and reducing food intake by activating GLP-1 and GIP receptors [1] - Roche disclosed that combining CT-388 with Zealand Pharma's pipeline drug could potentially create a "best-in-class" treatment option with better tolerability [1] - As of last Friday, Roche's stock price increased by 1.46%, with a year-to-date gain of approximately 5.4% [1] Industry Summary - The obesity market is currently dominated by Eli Lilly and Novo Nordisk, with sales expected to exceed $100 billion by 2030 [1]

Core Insights - Novo Nordisk has reported promising late-stage trial results for its new obesity treatment, Cagrilintide, which aims to provide an alternative to its successful drug Wegovy [1][5] Group 1: Clinical Trial Results - Early analysis from the phase 3 REDEFINE 1 trial indicated that Cagrilintide helped patients achieve an average weight reduction of 11.8% after 68 weeks, compared to 2.3% for the placebo group [2] - The treatment is characterized as a long-acting amylin analogue, which works by mimicking a hormone that increases satiety [3] - The side effects of Cagrilintide are reported to be mild to moderate gastrointestinal issues, with the treatment being described as "well-tolerated" [3][4] Group 2: Market Context and Competition - Novo Nordisk is pursuing Cagrilintide as a next-generation obesity treatment due to the success of its existing products, Ozempic and Wegovy, which are facing supply constraints and competition from generic alternatives [5] - Other companies, such as Roche and Zealand Pharma, are also developing amylin analogue treatments, indicating a competitive landscape in obesity therapies [6] Group 3: Analyst Insights - Analysts have noted that the side-effect profile of Cagrilintide is particularly promising, with expectations for a lower discontinuation rate compared to existing treatments like Wegovy and Zepbound [7] - The upcoming dedicated phase 3 RENEW trial will further investigate the efficacy and safety of Cagrilintide in patients with obesity without associated comorbidities, set to begin in late 2025 [8]